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Multiple myeloma is a prevalent and incurable disease, despite thedevelopment of new and effective drugs. The recent developmentof chimeric antigen receptor (CAR)T cells has shown impressive
results in the treatment of patients with relapsed or refractory hematologic
B-cell malignancies. In recent years, B-cell maturation antigen (BCMA) has
appeared as a promising antigen to target using a variety of immunotherapy
treatments, including CART cells, for patients with multiple myeloma. To
this end, we generated clinical-grade murine CART cells directed against
BCMA, named ARI2m cells. Having demonstrated its efficacy, and in an
attempt to avoid the immune rejection of CART cells by the patient, the
single chain variable fragment was humanized, creating ARI2h cells. ARI2h
cells showed comparable in vitro and in vivo efficacy to that of ARI2m cells,
and superiority in cases of high tumor burden disease. In terms of inflam-
matory response, ARI2h cells produced less tumor necrosis factor-α and
were associated with a milder in vivo toxicity profile. Large-scale expansion
of both ARI2m and ARI2h cells was efficiently conducted following Good
Manufacturing Practice guidelines, obtaining the target CART-cell dose
required for treatment of multiple myeloma patients. Moreover, we
demonstrated that soluble BCMA and BCMA released in vesicles both
affect CAR-BCMA activity. In summary, this study sets the bases for the
implementation of a clinical trial (EudraCT code: 2019-001472-11) to study
the efficacy of ARI2h-cell treatment for patients with multiple myeloma. 
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ABSTRACT
Introduction
Multiple myeloma (MM) remains an incurable hematologic malignancy respon-
sible for 15-20% of all blood cancers1,2 and new cases have been increasing, on aver-
age, by 0.8% each year over the past decade.3 The natural history of MM is relapse
until refractory disease without reaching a plateau of survival, with less than 10%
of patients achieving sustained complete remission beyond 5-10 years after autol-
ogous stem-cell transplantation.4 Moreover, patients are rarely cured after high-
dose chemotherapy followed by autologous stem-cell transplantation, indicating
that novel strategies are required to improve the survival of patients with
relapsed/refractory MM. 
In recent years, chimeric antigen receptor (CAR)T-cell immunotherapy, based on
the infusion of autologous T cells genetically modified to recognize an antigen
expressed on the tumor cell, has changed the modality of
treatment for certain hematologic malignancies.
Specifically, in acute lymphoblastic leukemia and lym-
phomas targeting CD19 outstanding responses have been
achieved from the use of CART cells.5-8 In MM, B-cell mat-
uration antigen (BCMA)9-11 has appeared as the most
promising target for CART-cell immunotherapy. 
Clinical studies in patients with relapsed/refractory MM
receiving CART-BCMA cells have documented excellent
responses.12 Unfortunately, however, patients end up relaps-
ing.12,13 Interestingly, in comparison to CART19, a higher
CART-cell dose is required to achieve responses, 150x106
CART cells being the the lowest dose required to obtain
response in patients who have relapsed after or are refracto-
ry to a median of seven lines of treatment.12,14 Moreover, it
has been shown that a deepening of the response is
obtained over time.12 In addition, the use of humanized or
human CAR instead of murine CAR is emerging as the cur-
rent trend in CART-cell immunotherapy.15,16
Here, using the same structure developed for CAR19
(ARI-0001), a CAR that has already been used in a phase I
clinical trial (NCT03144583) for B-cell malignancies at our
institution,17 we generated a murine CAR against BCMA
(ARI2m) and a humanized version (ARI2h) for academic
use. The efficacy and inflammatory response of both
ARI2m and ARI2h cells were compared. Both CART cells
showed comparable anti-MM activity. However, a greater
efficacy was observed for ARI2h cells in cases of high
tumor burden. The feasibility of clinical-grade expansion
was tested in parallel in two different institutions and suc-
cessfully achieved for both CAR. Finally, the impact of sol-
uble BCMA (sBCMA) on ARI2m cell activity was ana-
lyzed, demonstrating how sBCMA can negatively affect
CAR-BCMA activity. Overall, the results of this study
have set the bases for a multicenter clinical trial on the use




Research involving human materials was approved by
the Clinical Research Ethical Committee (Hospital Clinic,
Barcelona, Spain). Peripheral blood T cells were obtained
from healthy donors after informed consent. All animal
work was performed with approval from the Animal
Research Ethical Committee (Hospital Clínic, Barcelona,
Spain). 
Cloning and humanization strategy 
The anti-BCMA single chain variant fragment (scFv) was
designed from the J22.9 antibody.18 Human CD8a domains,
4-1BB and CD3 domains were obtained from the CART19
used at our Institution.17 Anti-CD19 scFv was substituted
for the anti-BCMA scFv of the J22.9 antibody. In order to
obtain ARI2h, the scFv sequence of the J22.9 antibody was
humanized using two predictive models (Blast and
Germline). Selected amino acids (excluding complementar-
ity-determining regions and Vernier zone) were substituted
for their homologous sequence in humans.
Predictive in silico models
Immunogenicity against MHC-I was predicted with
NetMHC-4.019-21 as previously described.15 In detail, binding
affinities of every 9-mer peptides from both scFv that are
not encoded by the human genome were evaluated for 12
HLA-I alleles (5 type A and 7 type B) to predict binding
affinity. As humanized ARI2h scFv contains human frame-
work regions, only sub-peptides from complementarity-
determining regions and Vernier zone were considered. The
affinity threshold to select only strong binders was <100
nM. To determine binding affinities, structural models
derived for each antibody-BCMA pair were built with
M4T22 using the crystal structure of the J22.9xi-
BCMAhuman complex (4ZFO)18 from the Protein Data
Bank23 as a template. The quality and stereochemistry of the
model was assessed using Prosa-II24 and PROCHECK,25
respectively. For each structural complex antibody-antigen
model a total of 100 minimization trajectories were per-
formed, followed by an estimation of the binding affinity as
the energy difference between the complex and its separat-
ed components (ddG). Minimization and ddG analysis
were carried out with Rosetta Design Suite.26,27 The quality
of the binding affinity model was very high28 because of the
high level of sequence identity between target sequences
and the template showing similar protein-protein interfaces
(Online Supplementary Figure S1D).
Clinical-grade production of ARI2 cells 
Lentiviral particles were produced inside a clean room
facility following Good Manufacturing Practice guidelines
as previously described.17. Clinical-grade ARI2h/ARI2m
cells were produced using CliniMACS Prodigy (Miltenyi,
Biotec) as described elsewhere.17
Further details of the methods are provided in the Online
Supplementary Methods.
Results
ARI2m cells demonstrate potent anti-myeloma activity
The ARI2m sequence (Online Supplementary Figure S1A)
contains the scFv sequence of the anti-BCMA antibody
J22.9,18 which has been shown to be effective against MM,29
and human CD8a, 4-1BB and CD3ζ as hinge, transmem-
brane, co-stimulatory and signaling domains (Figure 1A).
CART-cell transfection efficiencies varied between 30-60%
in different experiments. CAR expression was retained after
cryopreservation (Online Supplementary Figure S1B). The
efficacy of ARI2m cells was tested against ARP1 and U266
MM cells by co-culturing T cells and MM cells at an effec-
tor:target (E:T) ratio of 1:1 over 4 days. ARI2m cells effi-
ciently eliminated MM cells in comparison to untransduced
(UT) T cells (Figure 1B) while no cytotoxicity was observed
against a BCMA-negative cell line (K562) demonstrating the
specificity of ARI2m cells (Figure 1B). In addition, limiting
dilution cytotoxicity assays with E:T ratios from 1:1 to
1:0.125 demonstrated a high efficacy of ARI2m cells at
eliminating MM cells at a low E:T ratio at 36 h (Figure 1C),
and the effect continued to increase to 72 h (Online
Supplementary Figure S1C). 
The production of pro-inflammatory cytokines by
ARI2m cells was analyzed after co-culturing ARI2m cells
and MM cells at different E:T ratios, at 24 and 48 h. A high
interferon (IFN)γ production was observed at 24 h which
increased at 48 h (Figure 1D). Some IFNγ production was
detected for UT T cells, as expected, since UT T cells are
activated during in vitro expansion. Minimum levels of inter-
leukin (IL)6 were detected at 24 h, with the levels increasing
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at 48 h (Figure 1D). Tumor necrosis factor (TNF)α produc-
tion decreased at 48 h in comparison to that at 24 h, sug-
gesting that TNFα is produced early during CART-cell acti-
vation (Figure 1D). 
The in vivo efficacy of ARI2m cells was analyzed in a
murine model in which NSG mice received 1x106 ARP1
MM cells. Mice were treated 6 days later with either 10x106
UT cells or 10x106 T cells containing 2x106 ARI2m cells
(Figure 1E). ARI2m cells prevented disease progression and
performed better than UT T cells (Figure 1E, F). As expect-
ed, this translated into increased survival (Figure 1G).
Furthermore, analysis of mice tissues at the experimental
endpoint showed an absence of MM cells in the bone mar-
row and spleen (Figure 1H). T cells were mainly in the
spleen (Figure 1I), whereas CART cells proliferated mainly
in bone marrow, as indicated by a higher percentage of
CAR-BCMA for multiple myeloma
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Figure 1. ARI2m cells demonstrate potent in vitro and in vivo anti-myeloma activity. (A) Design of ARI2m. (B) Cytotoxicity assays of ARI2m against ARP1 and U266
(multiple myeloma cell lines) and non-myeloma K562 cells performed from 24-96 h. (C) Limiting dilution cytotoxicity assay against ARP1 and U266 cells performed
at ratios from 1:1 to 0.125:1 (T cell: tumor cell line) at 36 h. (D) Cytokine profile of interferon γ, interleukin 6 and tumor necrosis factor α after 24 h and 48 h of co-
culturing T cells and ARP1 cells. (E-J) In vivo efficacy of ARI2m cells. (E, F) Diagram of experimental design and quantification of disease progression by weekly bio-
luminescence imaging and overall survival of the different groups of mice (G). (H) Flow cytometry of bone marrow and spleen of mice at the end of the experiment.
(I) Percentage of total T cells and chimeric antigen receptor T cells in bone marrow and spleen ofn mice treated with ARI2m. (J). Soluble B-cell maturation antigen
from mice serum after being treated with ARI2m or UT T cells. *P<0.05. LTR: long terminal repeat; UT: untransduced; IFNγ: interferon γ; IL6: interleukin 6; TNFα:









CART cells from the whole T-cell population in bone mar-
row than in the spleen (Figure 1I). Moreover, sBCMA was
analyzed as an additional marker for MM progression in
mice serum. As expected, a high amount of sBCMA was
detected in mice treated with UT T cells while no sBCMA
was found in mice treated with ARI2m cells (Figure 1J).
Humanization of ARI2m does not change affinity 
binding against human B-cell maturation antigen 
and enhances cytotoxicity against highly advanced 
myeloma disease 
Early disappearance of CART cells15 is associated with
xenorecognition of the murine component of the CAR scFV
by the human immune system. To circumvent this problem,
we designed a humanized sequence of the scFv of ARI2m
(Online Supplementary Figure S1A). Two different humanized
variants were created based on two different predictive algo-
rithms (Blast and Germline) by substitution of amino acids
of the variable regions of heavy and light chains. In vitro com-
parison of the efficacy of both variants demonstrated that
the Germline variant had slightly higher anti-MM activity
(Figure 2A) and equal specificity, since neither of them elim-
inated K562 cells (Figure 2A). Therefore, the Germline vari-
ant, which was termed ARI2h, was selected for additional
characterization. Predictive in silico models for the immuno-
genicity of both scFv demonstrated higher immunogenicity
for ARI2m than for ARI2h (Figure 2B). Binding affinity pre-
diction of both scFv against murine and human BCMA
showed that both scFv bind to human BCMA with similar
affinity while being unable to bind murine BCMA (Figure
2C). A structural comparison between the two scFv showed
that most structural changes during the humanization were
concentrated in the heavy chain of the antibody.
Complementarity-determining regions on the antibody
included no mutations and presented almost no structural
drift (Figure 2D), reinforcing the idea that both antibodies
have an almost identical binding surface. Subsequently, we
analyzed whether T-cell transfection with either ARI2m or
ARI2h CAR constructs would lead to different phenotypes
in ARI2 cells. We did not observe any difference in either the
proportion of ARI2+CD4 and ARI2+CD8 cell populations
(Figure 2E) or the proportion of memory T-cell subsets
(Online Supplementary Figure S1E).
Moreover, as it was noted that the in vitro efficacy of
ARI2h was slightly lower than that of ARI2m cells (Figure
2A), a long-term cytotoxicity assay was performed in which
tumor and ARI2 cells were cultured together at a low E:T
ratio (0.125:1). This assay showed slower killing kinetics for
ARI2h cells, but an equal anti-MM activity at later time-
points (Figure 2F). Accordingly, T-cell proliferation upon
CAR-antigen binding was slower for ARI2h cells (Figure
2G). In addition, whereas the same level of IFNγ was pro-
duced by both CART cells, lower TNFα and similar IL6 pro-
duction was detected for ARI2h cells (Figure 2H). 
The anti-MM activity of ARI2h and ARI2m cells was fur-
ther evaluated using two different in vivo models of MM
(early and advanced disease models). Mice received MM
cells on day 0 and were treated with 5x106 CART cells on
day 6 or 14 to create an early and advanced model of dis-
ease, respectively (Figure 3A, B). In the early disease model,
ARI2h and ARI2m cells prevented MM progression equally
(Figure 3A, C). Around day 50, mice started to show signs of
toxicity, which were more severe in the ARI2m group and
translated into a lower survival rate for this group (Figure
3D). These results suggested that toxicity was related to a
global higher number of T cells proliferating in the ARI2m-
treated group, as previously observed.30 In the advanced dis-
ease model, whereas ARI2m abrogated disease progression
completely, minimal levels of MM disease were detected in
the ARI2h-treated group at certain time points (Figure 3B),
although this difference was not statistically significant
(Figure 3C). Interestingly, mice treated with ARI2h cells
again showed increased survival, consistent with lower tox-
icity, in comparison with that of mice treated with ARI2m
cells (Figure 3D). Accordingly, in both disease models, the
global number of T cells was higher for ARI2m than for
ARI2h cells (Figure 3E), which might explain the greater
xeno-graft-versus-host disease observed in the ARI2m-treat-
ed group. Importantly, the majority of T cells in bone mar-
row corresponded to CART cells, for both ARI2m and
ARI2h cells, and in both disease models (Figure 3E). Lastly,
analysis of mice serum showed that both CAR secreted
large amounts of IFNγ. However, and in agreement with
previous observations of slower kinetics for ARI2h cells,
IFNγ production was slower in the ARI2h group. Thus, in
the early model, IFNγ could not be detected in the ARI2h
group 3 days after CART-cell infusion but its levels was
higher at day 31 (Figure 3F). Similarly, in the advanced dis-
ease model, no IFNγ was detected at day 5 for ARI2h cells,
but levels increased at day 21 (Figure 3F).
These results suggested a faster activity of ARI2m than of
ARI2h cells, which in cases of high tumor burden, might
lead to faster exhaustion of CART cells and their disappear-
ance. To test this hypothesis, a third in vivo experiment with
a lower CART-cell dose (3x106) was performed. Disease bur-
den was higher at the time of CART-cell injection than in the
previous experiments (Figure 3B vs. Figure 4A). In this
model, neither ARI2m nor ARI2h cells could prevent disease
progression (Figure 4B). However, the performance of
ARI2h cells at slowing disease progression was better than
that of ARI2m cells (Figure 4B). At the last time-point, when
mice were euthanized due to disease progression and not to
xeno-graft-versus-host disease, T cells were almost unde-
tectable (Figure 4C). However, mice treated with ARI2h cells
had higher numbers of ARI2h cells in the bone marrow
(Figure 4C). These data suggest that slower CART-cell pro-
liferation could lead to longer CART-cell persistence and
superior antitumor activity in cases of high tumor burden.
To further support these findings, we exposed both ARI2m
and ARI2h cells to consecutive in vitro challenges with MM
(Figure 4D). In agreement with the lower ARI2m efficacy
observed in animals with a high tumor burden, these exper-
iments demonstrated more durable persistence for CD4 and
CD8 ARI2h cells, which was not consistent for ARI2m cells
(Figure 4E).
ARI2h cells induce less tumor necrosis factor α
production than do ARI2m cells 
Previous studies have shown that macrophages, after
being activated by CART cells, are the main producers of
IL6, IL1b and TNFα31,32 which lead to the development of
cytokine release syndrome (CRS) in patients. To further ana-
lyze the pro-inflammatory profile of both CAR, we there-
fore established an in vitro system adding macrophages.
Thus, effector and target cells were co-culture in the pres-
ence of macrophages (Figure 5A). The addition of
macrophages did not affect CART-cell cytotoxicity (Figure
5B). The level of IFNγ was only slightly increased but very
significant increases were detected for IL6, TNFα and IL1b,
the last one not being detected in the absence of
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Figure 2. Humanization of ARI2m into ARI2h and com-
parison of the affinity and immunogenicity of ARI2m vs
ARI2h. (see also Online Supplementary Figure S1). (A)
Limiting dilution cytotoxicity assay of ARI2m versus both
humanized versions (Blast and Germline). (B) Predicted
affinities of 9-mer peptides derived from either the
ARI2m or ARI2h single chain variant fragment (scFv)
against HLA-I. The total number of sites with predicted
affinity <100 nM is shown on the left, and specific inter-
actions of HLA-I alleles with each 9-mer peptide of the
scFv is shown on the right. (C) Estimation of the binding
affinity of both scFv against human and murine B-cell
maturation antigen (BCMA). The difference in Gibbs free
energy between the complex and its separated compo-
nents for each protein pair highlights the inability of any
of the antibodies to target murine BCMA. (D). Local struc-
tural comparison between the two scFv performed
through RMSD. Positions of the complementarity-deter-
mining regions are highlighted in green while sequence
differences between the two antibodies are mapped in
gray under the curve. The resolution of the template
structure of the antibody is represented as a dashed
line. The graphic shows low structural drift on the anti-
bodies’ complementarity-determining regions between
the two antibody variants. (E). Phenotype characteriza-
tion of T cells transduced with either ARI2m or ARI2h
chimeric antigen receptor construct and after being
expanded for 7 days (n=3). (F) Long-term cytotoxic assay
comparing ARI2m versus ARI2h cells against ARP1 (mul-
tiple myeloma cells) and K562 (non-myeloma cells) for
proliferation (G) and interferon γ, tumor necrosis factor α
and Interleukin 6 production (H). *P<0.05. UT: untrans-
duced; ddg: difference in Gibbs free energy; RMSD: root
mean square deviation; E:T; effector to target cell ratio;
CSFE: carboxyfluorescein succinimidyl ester; IFNγ: inter-
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Figure 3. In vivo efficacy of
ARI2m cells and ARI2h
cells. Mice received multi-
ple myeloma cells on day




in the early disease model
(A) and advanced disease
model (B) and quantified
(C). (D) Kaplan-Meier curve
representing the overall
survival of the different
groups of mice. (E) Total
CD3+ T cells and percent-
age of ARI2 cells from the
CD3+ T-cell populations
found in the bone marrow




interferon γ from murine
serum at days 3 and 31 for
the early disease model
and at days 5 and 21 for
the advanced disease
model. *P<0.05. MM: mul-
tiple myeloma; CAR:
chimeric antigen receptor;
BM: bone marrow; IFNγ:








macrophages (Figure 5C). Next, we compared the pro-
inflammatory activity of ARI2m cells and ARI2h cells over 2
days using this setting. We observed similar IFNγ, IL6 and
IL1b production for both CAR (Figure 5D) but TNFα pro-
duction was lower for ARI2h cells, consistent with the find-
ings of the long-term in vitro assay previously performed
(Figure 2H) and the lesser in vivo toxicity of ARI2h compared
to ARI2m cells. 
Efficient clinical production and activity of ARI2 cells
Pre-clinical data presented here support the development
of a phase I multicenter clinical trial for MM patients
(EudraCT code: 2019-001472-11) to evaluate the efficacy of
treatment with ARI2 cells. The feasibility of large-scale, clin-
ical-grade production was tested both for ARI2m and ARI2h
cells using T cells from healthy donors. A CART-cell produc-
tion system has already been established at our institution
and is being used in an ongoing phase I clinical trial with a
CAR19 product (ARI-0001).17 Four expansions were con-
ducted for each CAR in two different institutions. Both
ARI2m and ARI2h cells were efficiently expanded and the
required CART-cell dose (>150x106 CART cells)12 was
achieved in all cases (Figure 6A, B). Anti-MM activity for
both ARI2h and ARI2m cells was also demonstrated (Figure
6C). In both institutions, all productions achieved the mini-
mum threshold required for product release (Figure 6D, E).
Soluble and released B-cell maturation antigen affects
ARI2 cells activity
Clinical studies with CART19 in acute lymphoblastic
leukemia have shown that 1x106 CART cells/kg are suffi-
cient to achieve complete remission.5 In MM however a
higher dose is needed (>150x106).12 BCMA is cleaved and
released as sBCMA into the extracellular milieu.33 We
hypothesized that sBCMA can bind to CAR-BCMA, partial-
ly hampering its anti-MM activity, thereby explaining the
high CAR-BCMA dose required to achieve complete remis-
sion in MM patients. We therefore measured the amount of
sBCMA in serum from patients with monoclonal gam-
mopathy of undetermined significance, patients with newly
CAR-BCMA for multiple myeloma
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Figure 4. Humanization of ARI2m enhances cytotoxicity against highly advanced myeloma disease. (A) Schematic representation and images of an in vivo experi-
ment in mice receiving ARP1 multiple myeloma cells (MM) and treated with either ARI2m or ARI2h cells. (B) Disease progression was followed by weekly biolumines-
cence of the experiment in (A). (C) Total CD3+ T cells and percentage of ARI2 cells from the CD3+ T-cell population found in the bone marrow. (D) Graph showing the





diagnosed MM and MM patients at relapse. As expected,
we observed larger amounts of sBCMA in MM patients
(Figure 7A). 
To test whether sBCMA inhibits CART-cell activity, MM
cells were co-cultured with ARI2m cells in the presence of
recombinant BCMA protein. The results confirmed that
recombinant BCMA blocks the activity of ARI2m cells, in
terms of cytotoxicity and IFNγ production (Figure 7B). MM
patients had around 100 ng/mL of sBCMA and a titration
assay with recombinant BCMA demonstrated inhibition of
ARI2m-cell activity up to 32 ng/mL of BCMA (Figure 7C).
BCMA shedding is mediated by γ-secretase, which directly
cleaves and releases BCMA into the milieu, decreasing sur-
face BCMA expression. BCMA shedding can, therefore, be
blocked using γ-secretase inhibitors.33 To analyze the effect
of a γ-secretase inhibitor (DAPT), we measured membrane-
bound BCMA in MM cells and the amount of sBCMA
before and after treating MM cells with DAPT. As expected,
DAPT treatment increased BCMA surface expression in
MM cells and decreased the release of sBCMA (Figure 7D,
E). The increased membrane-bound BCMA and decreased
sBCMA associated with DAPT treatment were also detect-
ed after co-culturing MM cells with UT T cells (Figure 7D,
E). In the case of co-cultures of ARI2m and MM cells, the
addition of DAPT decreased the amount of sBCMA, as
expected. However, membrane-bound BCMA was poorly
detected because of the high ARI2m-cell activity in vitro,
eliminating MM cells (Figure 7D, E). Having demonstrated
that DAPT treatment prevents BCMA shedding, we tested
whether this effect results in enhanced ARI2m-cell activity.
This analysis was conducted in transwell plates, in which
untouched MM cells were placed in the upper well and co-
cultured ARI2m and MM cells in the lower well (Figure 7F).
In this setting, MM cells in the upper well released sBCMA
continuously. A cytotoxicity assay showed reduced ARI2m-
cell cytotoxicity and IFNγ production in the presence of
sBCMA (with MM cells in the upper well) than in the con-
trol without MM cells in the upper well (Figure 7G).
Moreover, the addition of DAPT to this transwell assay
enhanced the cytotoxicity and IFNγ production of ARI2m
cells without affecting the proliferation of ARI2m cells
(Figure 7G).
In addition, using confocal fluorescence microscopy we
observed that BCMA is released from MM cells in vesicles
(Figure 7H) through a mechanism that could also reduce
CART-cell activity. In order to confirm that these BCMA
vesicles could temporarily affect CAR-BCMA activity, MM
cells overexpressing BCMA fused to green fluorescent pro-
tein (MM-BCMA-GFP) were co-cultured with ARI2m cells
for 3 h and time-lapse in vivo imaging was performed. We
confirmed that BCMA released in vesicles bind to ARI2m
cells, distracting ARI2m cells from their target MM cells
(Figure 7I and Online Supplementary Movie S1). Moreover, we
also observed that, after being in contact with MM cells,
ARI2m cells could acquire BCMA in their membranes from
the surface of the MM cells and, as a consequence, fratricide
was observed between ARI2m cells (Figure 7J and Online
Supplementary Movie S2). To further confirm this event,
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Figure 5. ARI2h cells induce less tumor necrosis factor α production than do ARI2m cells. (A) Schematic representation of monocyte and T-cell isolation from the
same buffy coat, differentiation of the monocytes into macrophages, in vitro expansion and co-culture of chimeric antigen receptor T (CART) cells with multiple myelo-
ma (MM) cell lines. (B) Cytotoxicity and (C) production of the cytokines interferon γ, interleukin 6, tumor necrosis factor α and interleukin 1b by ARI2m cells co-cultured
with ARP1 cells with or without macrophages. (D) Cytokine production over 48 h after co-culturing ARI2m/ARI2h with macrophages and ARP1 MM cells. Macrophages
were added at a 1:3 macrophage:CART ratio. *P<0.05. **P<0.0001. M-CSF: macrophage colony-stimulating factor; UT: untransduced; Mac: macrophages; IFNγ:
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Figure 6. Efficient clinical production
and activities of ARI2m and ARI2h
cells. (A, B) Clinical expansion of ARI2m
and ARI2h cells showing the total T-cell
(A) and total chimeric antigen receptor
T-cell numbers (B) achieved at the end
of the expansion. (C) Cytototoxicy
assays against the U266 multiple
myeloma cell line of both ARI2m and
ARI2h cells at the end of the expansion.
Results from (A-C) are the median of
four clinical expansions of ARI2m and
ARI2h cells. (D, E). Detailed comparison
of the four clinical productions per-
formed in two different institutions,
showing the percentage of each cell
population achieved (D) and the speci-
fied parameters for product release (E).
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Figure 7. Soluble and released B-cell maturation antigen affects the activity of ARI2 cells. (A) Measurement of soluble B-cell maturation antigen (sBCMA) from
patients with monoclonal gammopathy of undetermined significance, multiple myeloma (MM) at diagnosis and MM at relapse. (B) Cytotoxicity assay and interferon
γ production of ARI2m cells co-cultured with ARP1 MM cells, adding recombinant BCMA protein (BCMA) at 10,000 ng/mL. (C) Cytotoxicity assays (at 24 h) of ARI2m
cells with ARP1 MM cells adding recombinant BCMA at the indicated doses. (D, E) Mean fluorescence intensity of BCMA (D) and concentration of sBCMA (E) of ARP1
MM cells alone or in co-culture with either ARI2m or UT T cells with or without DAPT. (F) Design of the cytotoxic assays in transwell plates to analyze the impact of
sBCMA and DAPT. ARI2m cells and ARP1 cells were co-cultured in the well, and additional ARP1 cells were added to the transwells as a source of continuous release
of sBCMA. (G) Cytotoxicity, interferon γ production and T-cell proliferation in the experiment described in (F). (H) Confocal fluorescence image of MM cells stained
with a cell tracker, CMAC, in which BCMA is visualized with a monoclonal anti-BCMA. (I, J) Time lapse images from two different in vivo time lapse experiments over
3 h of ARI2m cells stained with the cell tracker, CMAC, and co-cultured with either RPMI MM cells (I) or ARP1 MM cells (J) overexpressing BCMA in green fluorescent
protein (GFP) (see also Online Supplementary Movies S1 and S2). (K) Co-culture assay of T cells with MM-RPMI cells overexpressing BCMA-GFP to which latrunculin
A was added in parallel. Percentage of T cells acquiring BCMA-GFP on their surface is shown. (L). MM-RPMI cells and ARI2m cells were co-cultured for 2 h to allow
transfer of BCMA-GFP to ARI2m cells, then ARI2m cells were sorted and added into a 48 h cytotoxicity assay against RPMI-MM cells. *P<0.05. **P<0.0001. MGUS:
monoclonal gammopathy of undetermined significance; Dx: diagnosis; E:T: effector:target cell ratio; IFNγ: interferon γ; UT: untransduced; MFI: mean fluorescence







ARI2m and MM cells co-cultured in the presence of a trogo-
cytosis inhibitor (latrunculin A) showed a decreased percent-
age of BCMA acquisition by ARI2m cells (Figure 7K). In
addition, after acquiring BCMA in their membranes, ARI2m
cells showed decreased anti-MM activity (Figure 7L).
Discussion
BCMA was identified in 201310 as the most promising
antigen for CART-cell immunotherapy for the treatment of
patients with relapsed/refractory MM, a finding which was
confirmed in different clinical studies in MM patients12,13 and
led us to develop our murine CAR-BCMA cells with 4-1BB
as a co-stimulatory domain (ARI2m cells). ARI2m cells
demonstrated strong anti-MM activity which is retained in
their humanized version (ARI2h cells). Additionally, a
greater efficacy of ARI2h versusARI2m cells was observed in
vivo in mice with high tumor burden. Our results set the
bases for a multicenter phase I/II clinical trial of treatment
with ARI2h cells for patients with relapsed/refractory MM
in Spain. 
The success of BCMA as a target for CART-cell
immunotherapy was demonstrated for the first time in
patients with a CAR-BCMA with CD28 as the co-stimula-
tory domain. However, this CAR displayed marked
toxicity.14 The CD28 was therefore replaced by 4-1BB: the
new CAR (bb2121) demonstrated manageable toxicity and
it was found that a minimum dose of 150x106 CART cells
was required to obtain responses.12 In parallel, two other
studies,13,34 demonstrated that a lower number of previous
treatments is associated with better responses, and that
short-term CART-cell expansion is more consistent after
lymphodepletion.34 Different factors influence CART-cell
expansion and persistence, which enhance the long-term
control of the disease.5,12,13,34 Work needs to be done to
improve these aspects of CAR-BCMA therapy, because a
high number of MM patients end up relapsing.12,13 One of the
suggested reasons for this is the limited persistence of CART
cells. In this regard, human or humanized CAR, by avoiding
the immunological reaction of the human immune system
against the murine components of the scFv of the CAR,
might increase the persistence of CART cells.15,16,30 Based on
previous studies, and supported by our results showing that
both ARI2m and ARI2h cells prevented disease progression
equally, we selected ARI2h cells, which are humanized
CAR-BCMA cells, to be used for a clinical trial for MM
patients (EudraCT code: 2019-001472-11).
Long-term CART-cell persistence is also associated with
durability of remission.5,12,13,34 Factors influencing long-term
CART-cell persistence include the exhaustion profile of
CART cells29,35 and the affinity for the target antigen in com-
bination with the co-stimulatory domain of CART cells. In
this regard, studies on CART19 with CD28 and 4-1BB
demonstrated that strong activation of CART cells, due to
high affinity or high expression of the target antigen com-
bined with the CD28 domain, leads to faster CART-cell pro-
liferation with increased exhaustion and shorter persistence.
Contrariwise, slower CART-cell activation, due to a lower
affinity to the target antigen or to the 4-1BB domain, reduces
exhaustion, thereby improving persistence.35-39 Here, even
though ARI2m and ARI2h cells had the 4-1BB co-stimulato-
ry domain and presented the same affinity against human
BCMA, ARI2h cells had slower kinetic activity, and demon-
strated greater efficacy than ARI2m cells in a murine model
of high tumor burden, and longer persistence after consecu-
tive challenges to tumor cells.
CRS and neurotoxicity are common after the administra-
tion of CART cells.5,12,13,34,40-42 Although these problems are
efficiently managed by following international guidelines,43,44
the ideal CART-cell treatment should try to minimize the
development of CRS. Here, the use of ARI2h cells instead of
ARI2m was further supported by the observation of lower
TNFα production in vitro with the ARI2h cells. Whereas IL6
is the effector cytokine for CRS,31,45,46 and exponentially
increases as CRS develops, other cytokines such as TNFα
and IL1b31,32 are the main initiators of CRS, as they are pro-
duced at early time points by monocytes and macrophages
once they are activated by IFNγ produced by CART cells. In
fact, TNFα, acts as an initiator cytokine orchestrating the
cytokine cascade in many inflammatory diseases, appearing
as a therapeutic target in inflammatory diseases.46 Here, our
in vitro model with macrophages mimicking a model more
similar to the in vivo scenario, demonstrated that ARI2h cells
induced less TNFα production by macrophages, a relevant
finding, as CRS in MM patients after CAR-BCMA treatment
associates with a higher peak of TNFα.12 Moreover, CAR
with faster kinetics associate with higher CRS,37 suggesting
that the slower kinetics of ARI2h cells in comparison to
ARI2m cells might also explain the observed lower level of
in vivo toxicity.
Last, we analyzed the impact of sBCMA on CART-cell
activity. Even though studies with CAR-BCMA in MM have
not found any correlation between sBCMA and CART-cell
activity,10,12,34,47 we observed that the high in vitroCART activ-
ity rapidly eliminating MM cells impeded a proper analysis
of the role of sBCMA in preclinical studies. Our in vitro mod-
els performed at a low CAR-BCMA:MM ratio, with the cre-
ation of an environment with continuous release of sBCMA,
and the addition of a γ-secretase inhibitor confirmed the
negative impact of sBCMA on CAR-BCMA activity.
Moreover, we observed that BCMA is also released in vesi-
cle structures, distracting CART cells from their targets, and
that BCMA can be transferred to CART cells through a
mechanism which appears to be trogocytosis, a finding
already made for CART19 cells,48 causing decreased anti-
MM activity of the ARI2m cells.
In conclusion, we have developed CAR-BCMA cells with
4-1BB as a co-stimulatory domain which have been human-
ized, retaining high efficacy and demonstrating less toxicity
than their murine counterparts. ARI2 cells can be efficiently
expanded under Good Manufacturing Practice conditions
for  use in a clinical trial. Moreover, we demonstrated that
sBCMA and BCMA released from MM cells can affect
CART-cell activity.
Disclosures
No conflicts of interests to disclose.
Contributions
LPA and BMA designed the study, LPA performed in vitro and
in vivo experiments. GS performed clonings, virus production and
in vivo experiments. LPA and BMA analyzed data and wrote the
manuscript. AN designed the scFv of ARI2m and provided viral
vector for GFP-Ffluc. MC and AA provided advice for experi-
ments. AA performed some of the CART in vitro expansions. MJ,
SI and AL performed clinical grade ARI2 production. JB and NFF
performed predictive models for bind-ing affinity. CB performed cell
sortings. AUI provided funding and constructive ideas. All authors
reviewed the manuscript.
CAR-BCMA for multiple myeloma
haematologica | 2021; 106(1) 183
Acknowledgments
We acknowledge the Multiple Myeloma Research Center (Little
Rock, AK, USA) for providing the ARP1 cell line and the Confocal
Fluorescence Microscopy facilities at the University of Barcelona.
Funding
Celgene and the Carlos III Institute of Health  (project:
PI17/01043) provided funding for all in vitro and in vivo studies.
L. Perez-Amill et al.
184 haematologica | 2021; 106(1)
References
   1. Palumbo A, Anderson K. Multiple myeloma.
N Engl J Med. 2011;364(11):1046-1060.
    2. Kumar SK, Callander NS, Alsina M, et al.
Multiple myeloma, version 3.2017, NCCN
clinical practice guidelines in oncology. J Natl
Compr Canc Netw. 2017;15(2):230-269.
   3. Cancer Stat Facts: Myeloma. National
Cancer Institute Surveillane, Epidemiology,
and End Results Program Web site. Available
at http://seercancergov/statfacts/html/mul-
myhtml. [Accessed January 2, 2020]
    4.Martinez-Lopez J, Blade J, Mateos MV, et al.
Long-term prognostic significance of
response in multiple myeloma after stem cell
transplantation. Blood. 2011;118(3):529-534.
    5.Maude SL, Laetsch TW, Buechner J, et al.
Tisagenlecleucel in children and young adults
with B-cell lymphoblastic leukemia. N Engl J
Med. 2018;378(5):439-448.
   6. Schuster SJ, Svoboda J, Chong EA, et al.
Chimeric antigen receptor T cells in refracto-
ry B-cell lymphomas. N Engl J Med. 2017;
377(26):2545-2554.
   7. Park JH, Riviere I, Gonen M, et al. Long-term
follow-up of CD19 CAR therapy in acute
lymphoblastic leukemia. N Engl J Med.
2018;378(5):449-459.
   8.Neelapu SS, Locke FL, Bartlett NL, et al.
Axicabtagene ciloleucel CAR T-cell therapy
in refractory large B-cell lymphoma. N Engl
J Med. 2017;377(26): 2531-2544.
   9.O'Connor BP, Raman VS, Erickson LD, et al.
BCMA is essential for the survival of long-
lived bone marrow plasma cells. J Exp Med.
2004;199(1):91-98.
 10.Carpenter RO, Evbuomwan MO, Pittaluga
S, et al. B-cell maturation antigen is a prom-
ising target for adoptive T-cell therapy of
multiple myeloma. Clin Cancer Res.
2013;19(8):2048-2060.
 11.Novak AJ, Darce JR, Arendt BK, et al.
Expression of BCMA, TACI, and BAFF-R in
multiple myeloma: a mechanism for growth
and survival. Blood. 2004;103(2):689-694.
 12. Raje N, Berdeja J, Lin Y, et al. Anti-BCMA
CAR T-cell therapy bb2121 in relapsed or
refractory multiple myeloma. N Engl J Med.
2019;380(18):1726-1737.
 13. Zhao WH, Liu J, Wang BY, et al. A phase 1,
open-label study of LCAR-B38M, a chimeric
antigen receptor T cell therapy directed
against B cell maturation antigen, in patients
with relapsed or refractory multiple myelo-
ma. J Hematol Oncol. 2018;11(1):141.
 14.Ali SA, Shi V, Maric I, et al. T cells expressing
an anti-B-cell maturation antigen chimeric
antigen receptor cause remissions of multi-
ple myeloma. Blood. 2016;128(13):1688-
1700.
 15. Sommermeyer D, Hill T, Shamah SM, et al.
Fully human CD19-specific chimeric antigen
receptors for T-cell therapy. Leukemia.
2017;31(10):2191-2199.
 16. Turtle CJ, Hanafi LA, Berger C, et al. CD19
CAR-T cells of defined CD4+:CD8+ com-
position in adult B cell ALL patients. J Clin
Invest. 2016;126(6):2123-2138.
 17.Castella M, Boronat A, Martin-Ibanez R, et
al. Development of a novel anti-CD19
chimeric antigen receptor: a paradigm for an
affordable CAR T cell production at aca-
demic institutions. Mol Ther Methods Clin
Dev. 2018;12:134-144.
 18.Oden F, Marino SF, Brand J, et al. Potent anti-
tumor response by targeting B cell matura-
tion antigen (BCMA) in a mouse model of
multiple myeloma. Mol Oncol. 2015;9(7):
1348-1358.
 19. Lundegaard C, Lamberth K, Harndahl M,
Buus S, Lund O, Nielsen M. NetMHC-3.0:
accurate web accessible predictions of
human, mouse and monkey MHC class I
affinities for peptides of length 8-11. Nucleic
Acids Res. 2008;36(Web Server issue):W509-
512.
 20.Andreatta M, Nielsen M. Gapped sequence
alignment using artificial neural networks:
application to the MHC class I system.
Bioinformatics. 2016;32(4):511-517.
 21.Nielsen M, Andreatta M. NetMHCpan-3.0;
improved prediction of binding to MHC
class I molecules integrating information
from multiple receptor and peptide length
datasets. Genome Med. 2016;8(1):33.
 22. Fernandez-Fuentes N, Madrid-Aliste CJ, Rai
BK, Fajardo JE, Fiser A. M4T: a comparative
protein structure modeling server. Nucleic
Acids Res. 2007;35(Web Server issue):W363-
368.
 23. Berman HM, Westbrook J, Feng Z, et al. The
protein data bank. Nucleic Acids Res.
2000;28(1):235-242.
 24. Sippl MJ. Recognition of errors in three-
dimensional structures of proteins. Proteins.
1993;17(4):355.
 25. Laskowski RA, MacArthur MW, Moss DS,
Thornton J. PROCHECK: a program to
check the sterochemical quality of protein
structures. J Appl Cryst. 1993;26:283-291.
 26. Fleishman SJ, Leaver-Fay A, Corn JE, et al.
RosettaScripts: a scripting language interface
to the Rosetta macromolecular modeling
suite. PLoS One. 2011;6(6):e20161.
 27. Leaver-Fay A, Tyka M, Lewis SM, et al.
ROSETTA3: an object-oriented software
suite for the simulation and design of macro-
molecules. Methods Enzymol. 2011;487:
545-574.
 28. Baker D, Sali A. Protein structure prediction
and structural genomics. Science. 2001;294
(5540):93-96.
 29. Bluhm J, Kieback E, Marino SF, et al. CAR T
cells with enhanced sensitivity to B cell mat-
uration antigen for the targeting of B cell
non-Hodgkin's lymphoma and multiple
myeloma. Mol Ther. 2018;26(8): 1906-1920.
 30. Smith EL, Staehr M, Masakayan R, et al.
Development and evaluation of an optimal
human single-chain variable fragment-
derived BCMA-targeted CAR T cell vector.
Mol Ther. 2018;26(6):1447-1456.
 31.Giavridis T, van der Stegen SJC, Eyquem J,
Hamieh M, Piersigilli A, Sadelain M. CAR T
cell-induced cytokine release syndrome is
mediated by macrophages and abated by IL-
1 blockade. Nat Med. 2018;24(6):731-738.
 32.Norelli M, Camisa B, Barbiera G, et al.
Monocyte-derived IL-1 and IL-6 are differ-
entially required for cytokine-release syn-
drome and neurotoxicity due to CAR T
cells. Nat Med. 2018;24(6):739-748.
 33. Laurent SA, Hoffmann FS, Kuhn PH, et al. γ-
Secretase directly sheds the survival receptor
BCMA from plasma cells. Nat Commun.
2015;6:7333.
 34.Cohen AD, Garfall AL, Stadtmauer EA, et al.
B cell maturation antigen-specific CAR T
cells are clinically active in multiple myelo-
ma. J Clin Invest. 2019;129(6):2210-2221.
 35. Salter AI, Ivey RG, Kennedy JJ, et al.
Phosphoproteomic analysis of chimeric anti-
gen receptor signaling reveals kinetic and
quantitative differences that affect cell func-
tion. Sci Signal. 2018;11(544).
 36. Long AH, Haso WM, Shern JF, et al. 4-1BB
costimulation ameliorates T cell exhaustion
induced by tonic signaling of chimeric anti-
gen receptors. Nat Med. 2015;21(6):581-590.
 37.Milone MC, Fish JD, Carpenito C, et al.
Chimeric receptors containing CD137 signal
transduction domains mediate enhanced
survival of T cells and increased
antileukemic efficacy in vivo. Mol Ther.
2009;17(8):1453-1464.
 38.Wherry EJ, Kurachi M. Molecular and cellu-
lar insights into T cell exhaustion. Nat Rev
Immunol. 2015;15(8):486-499.
 39. Smith-Garvin JE, Koretzky GA, Jordan MS.
T cell activation. Ann Rev Immunol.
2009;27:591-619.
 40. Schuster SJ, Svoboda J, Chong EA, et al.
Chimeric antigen receptor T cells in refracto-
ry B-cell lymphomas. N Engl J Med.
2017;377(26):2545-2554.
 41. Locke FL, Neelapu SS, Bartlett NL, et al.
Phase 1 results of ZUMA-1: a multicenter
study of KTE-C19 anti-CD19 CAR T cell
therapy in refractory aggressive lymphoma.
Mol Ther. 2017;25(1):285-295.
  42. Shah N, Alsina M, Siegel DS, et al. Initial
results from a phase 1 clinical study of
bb21217, a next-generation anti BCMA CAR
T therapy. Blood. 2018;132(Suppl 1):488.
 43. Porter D, Frey N, Wood PA, Weng Y, Grupp
SA. Grading of cytokine release syndrome
associated with the CAR T cell therapy tis-
agenlecleucel. J Hematol Oncol. 2018;11
(1):35.
 44. Lee DW, Santomasso BD, Locke FL, et al.
ASTCT consensus grading for cytokine
release syndrome and neurologic toxicity
associated with immune effector cells. Biol
Blood Marrow Transplant. 2019;25(4):625-
638.
 45.Hunter CA, Jones SA. IL-6 as a keystone
cytokine in health and disease. Nat
Immunol. 2015;16(5):448-457.
 46. Parameswaran N, Patial S. Tumor necrosis
factor-α signaling in macrophages. Crit Rev
Eukaryot Gene Expr. 2010;20(2):87-103.
 47. Friedman KM, Garrett TE, Evans JW, et al.
Effective targeting of multiple B-cell matura-
tion antigen-expressing hematological
malignances by anti-B-cell maturation anti-
gen chimeric antigen receptor T Cells. Hum
Gene Ther. 2018;29(5):585-601.
 48.Hamieh M, Dobrin A, Cabriolu A, et al.
CAR T cell trogocytosis and cooperative
killing regulate tumour antigen escape.
Nature. 2019;568(7750):112-116.
